Silosin

Quick links to important sections

Silosin

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Silosin

What is Silosin? - Overview

Silodosin is a medicine specifically designed for adult men to help ease symptoms related to a non-cancerous enlargement of the prostate gland, known as benign prostatic hyperplasia (BPH). It belongs to a specialized group of medications called alpha-blockers.

Property Description
Active ingredient Silodosin
Form Oral Capsule
Pharmacological class Alpha-1 Adrenergic Receptor Antagonist (Alpha-Blocker)
Common use Management of lower urinary tract symptoms associated with BPH
Origin Synthetic, Small Molecule Inhibitor

Silodosin is a synthetic, single-ingredient, prescription-only medicine formulated as an oral capsule. It is classified as an Alpha-1 adrenergic receptor antagonist, acting as an adrenolytic agent to modulate muscle tone in the lower urinary tract.

Pharmacological Classification and Mechanism Principle

Silodosin is clinically recognized as a highly selective alpha-1A-adrenoceptor antagonist. This selectivity is a differentiating factor, as it targets alpha-1A receptors predominantly concentrated in the prostate and bladder neck, which distinguishes its action from that of less selective alpha-blockers.

This medicine's general purpose is to improve the flow of urine by initiating targeted muscle relaxation in the urinary passage. Silodosin is in a class of medications called alpha-blockers used to relieve symptoms of BPH by relaxing the muscles of the bladder and prostate. This action aims to reduce resistance and relieve mechanical obstruction associated with restricted urinary voiding.

Regulatory References

  1. U.S. National Library of Medicine
  2. MedlinePlus

What side effects are possible with Silosin?

Silosin: Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety restrictions for Silosin, based strictly on government regulatory documents.

Frequency-Classified Adverse Reactions

Side effects are classified by how often they occurred in clinical studies:

  • Very Common (may affect more than 1 in 10 people):
    • Retrograde ejaculation (ejaculation with reduced or no semen).
  • Common (may affect up to 1 in 10 people):
    • Dizziness, particularly when standing up quickly (orthostatic hypotension).
    • Headache.
    • Nasal congestion.
  • Uncommon (may affect up to 1 in 100 people):
    • Syncope (fainting).
    • Diarrhea, Nausea.

Clinically Significant and System-Organ Risks

Adverse events are also organized by the body system affected:

  • Reproductive System: Ejaculation disorders are the most common adverse reaction.
  • Eye Disorders: Use of Silosin has been associated with Intraoperative Floppy Iris Syndrome (IFIS), a complication that may occur during cataract or glaucoma surgery. Surgeons should be informed if the medicine is being, or has been, taken.
  • Immune System: Serious, rare hypersensitivity reactions, such as angioedema, have been documented.

Safety-Related Restrictions and Contraindications

Silosin is subject to specific safety limitations defined in regulatory labeling:

  • Contraindications (Situations Where Use is Prohibited): Silosin must not be used by patients with severe renal impairment or severe hepatic impairment. It is also contraindicated for patients with known hypersensitivity to Silosin or excipients.
  • Drug Interactions: Use is contraindicated when co-administered with other alpha1-adrenoceptor antagonists or strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Silosin is officially documented to result from an exaggeration of the drug's primary effects, leading to severe hypotension (low blood pressure). This condition typically manifests as profound postural hypotension—a significant drop in blood pressure when changing position—which may present with symptoms such as dizziness, lightheadedness, or blurred vision.

Required Emergency Actions

The most serious outcomes documented for an overdose include syncope (fainting) or cardiovascular collapse. Regulatory authorities mandate that immediate emergency medical attention must be sought for any suspected overdose. If a person has collapsed, is experiencing trouble breathing, or has had a seizure, emergency services must be called immediately.

Supportive Management

Official labeling states that no specific antidote is known for Silosin overdose. Consequently, management is symptomatic and supportive, focused strictly on restoring and maintaining cardiovascular stability. Treatment procedures officially described may include placing the individual in a supine position, followed by the administration of intravenous fluids and the use of vasopressors if required. Monitoring of renal function is also described as a supportive measure. Documentation notes that dialysis is unlikely to be beneficial due to the drug's high plasma protein binding.

Therapeutic Uses of Silosin

Quick Facts

  • Primary Use: Management of signs and symptoms related to Benign Prostatic Hyperplasia (BPH) in adult men.
  • Therapeutic Role: Helps alleviate lower urinary tract symptoms (LUTS).
  • Associated Benefits: May help improve urine flow rate and address discomfort linked to BPH.

Silosin is an agent utilized in adult men for the management of symptoms associated with Benign Prostatic Hyperplasia (BPH), which is the non-cancerous enlargement of the prostate gland. The compound is specifically indicated for the treatment of signs and symptoms of BPH, which are collectively known as Lower Urinary Tract Symptoms (LUTS).

The therapeutic purpose of Silosin is to contribute to the relief of these urinary issues. This may include helping to address difficulty urinating, such as hesitation, a weak stream, and the sensation of incomplete bladder emptying. Furthermore, the use of this agent is associated with potential improvements in irritative LUTS, which encompass urinary frequency and urgency. Through the treatment of these symptoms, Silosin may assist in maintaining the maximum urinary flow rate, which is a key measure in BPH management.

Eligibility and Restrictions for Use

Eligibility to Use Silodosin (Silosin)

Silodosin is a medicine approved only for the treatment of symptoms associated with Benign Prostatic Hyperplasia (BPH) in Adult Men (18 years and older). Official regulatory labeling specifies strict exclusions and conditions for use based on gender, age, organ function, and concurrent medications.

Populations Excluded or Contraindicated

Category Exclusion Status
Gender Not Indicated for women (safety and efficacy not established)
Age Not Indicated for the pediatric population (under 18 years)
Severe Renal Impairment Contraindicated (CCR < 30 mL/min)
Severe Hepatic Impairment Contraindicated (Child-Pugh Class C)
Strong CYP3A4 Inhibitors Contraindicated (e.g., ketoconazole, ritonavir)

Conditional or Restricted Use

Use of Silodosin is restricted in certain cases, requiring either a mandatory dose change or specific caution as stated in the label:

  • Moderate Renal Impairment (CCR 30 to 50 mL/min) requires a mandatory dose reduction to 4 mg once daily.
  • The medicine is not recommended for patients with established orthostatic hypotension or for those scheduled for cataract surgery.

What should I know about interactions with other medicines?

The official regulatory profile for Silodosin is structured by specific pharmacokinetic and pharmacodynamic constraints. Co-administration with strong CYP3A4 inhibitors, such as ketoconazole or ritonavir, is contraindicated because these agents significantly increase Silodosin’s systemic exposure, raising both the maximum plasma concentration (mathbfC max) and overall AUC. The combination with any other alpha-blocker is also contraindicated due to the anticipated enhancement of hypotensive effects.

The concomitant use of strong P-glycoprotein (P-gp) inhibitors (like cyclosporine) is not recommended, as Silodosin is a P-gp substrate, which can further elevate drug levels. A key pharmacodynamic interaction risk exists with PDE5 inhibitors (e.g., sildenafil), where co-administration may cause symptomatic hypotension; caution is advised.


Population-Specific and Food Notes

  • Renal Impairment: The drug is contraindicated in severe renal impairment (Creatinine Clearance < 30 mL/min). In patients with moderate renal impairment, Silodosin’s plasma concentrations are approximately three times higher than normal, amplifying potential interactions.
  • Hepatic Impairment: Use is contraindicated in severe hepatic impairment (Child-Pugh Class C).
  • Food Effect: Administration with a moderate-fat, moderate-calorie meal consistently reduces the drug’s systemic absorption and peak plasma levels.
  • Alcohol: Consumption of alcohol may increase the risk of side effects related to hypotension.

Mechanism of Action

The mechanism of action for Silosin (Silodosin) is characterized by its high specificity as a selective competitive antagonist of the Alpha-1A Adrenoceptor (alpha1 A-AR). These receptors are densely concentrated on the smooth muscle cells of the prostate and bladder neck, which are key targets for modulating tension in the urinary passage.

By physically blocking the alpha1 A-AR, Silosin prevents the endogenous neurotransmitter norepinephrine from initiating the contraction signal. This molecular blockade interrupts the Gq-mediated cellular cascade, preventing the subsequent release of intracellular calcium ( Ca^2+) ions. Since Ca^2+ is essential for smooth muscle contraction, this inhibition induces a state of muscular relaxation throughout the prostatic urethra.

The physiological consequence is a reduction of dynamic muscular resistance—the active tension exerted by the muscle tissue—at the bladder outlet. This action is specific to the dynamic muscular component and does not address the static physical mass of the prostate.

Dosage and Administration Information

How Silosin is Used: Official Administration Guidelines

Silosin, or silodosin, is administered through the oral route only, intended for the management of lower urinary tract symptoms associated with BPH in adult men. Its usage is defined by parameters concerning dosage, frequency, and timing in relation to meals.


Standard Dosing and Administration Protocol

The medicine is supplied as hard capsules in strengths of 4 mg and 8 mg. The standard recommended dosage for the approved indication is 8 mg taken once daily.

Instruction Type Official Guideline
Route of Administration Oral use only.
Dosing Frequency Once daily (qDay).
Timing in Relation to Meals Must be taken in conjunction with a meal.
Handling The capsule is typically swallowed whole. It must not be crushed or chewed.

Population-Specific Dosing Rules

Official labeling defines dose modifications based on kidney function. The use of silodosin is generally not recommended in patients with severe hepatic (liver) or severe renal (kidney) impairment.

For patients with moderate renal impairment (creatinine clearance CLCR 30 to < 50 mL/min), a reduced dose of 4 mg once daily is the required starting regimen. No specific dose adjustment is typically needed for older adults. If a dose is missed, the patient should take it as soon as the omission is noticed, but a double dose must not be taken to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Silosin

The primary body of research on Silosin consists of short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in adult men with moderate-to-severe Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). Researchers used a rigorous, double-blind approach, meaning neither the patients nor the doctors knew whether the medicine or an inactive placebo was being received. Research examined changes in urinary symptoms and was applied in studies examining patient-reported experiences.

How Core Efficacy Outcomes Were Measured in Trials

Outcomes related to physical discomfort were evaluated using specific, standardized tools. A key tool used was the International Prostate Symptom Score (IPSS), where patients report symptom frequency. Research examined the total IPSS score and subscores for both voiding and storage symptoms. Studies also monitored the Maximum Urinary Flow Rate ( Qmax), which is a functional measure tracked in BPH research.

Research reported measurements related to symptom outcomes. For the primary measure—the IPSS total score—short-term trials reported patterns of change in the score measurements across the groups studied over the defined 12-week study period. Studies report how symptoms evolved in the observed populations, and these findings describe group patterns, not personal outcomes.

Long-Term Studies and Follow-Up Data

The main efficacy data from the most controlled settings was observed in the short-term window. For longer observation, studies often transition into open-label extension studies. These extended follow-up studies have monitored patient responses for periods up to one year (52 weeks) and, in some observational settings, even longer. These findings help contextualize how patients reported their experience over time, but they are derived from settings that did not include a placebo comparator.

What Is Still Uncertain About the Research

One key limitation is that the primary, most reliable, placebo-controlled follow-up durations were limited to approximately 12 weeks. Consequently, long-term effects are not fully established and long-term outcomes are not well characterized by high-quality controlled data. Additionally, while studies report how symptoms evolved in the observed populations, findings were mixed for certain functional measures, like Qmax. Some reports indicated that the measured change in urinary flow rate over the placebo was not statistically distinct in every initial trial. This suggests that reported outcomes were varied for certain measures, and data are still emerging to fully contextualize some of the findings.

Key Studies & References

  1. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)
  2. Silodosin is effective for treatment of LUTS in men with BPH: a systematic review (2013)
  3. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study

Frequently Asked Questions (FAQ)

Common questions about Silosin (FAQ)


Q: How quickly should I expect to feel the effects of Silosin?

A: Silosin is designed to work by relaxing muscles in the prostate and bladder neck to ease urinary flow. Regulatory studies used to assess effectiveness typically monitor for changes in BPH symptoms over several weeks of continuous treatment. Symptom improvement may be observed gradually. Symptom changes are typically tracked using standardized tools by healthcare providers.

Q: What happens if I accidentally miss a dose of Silosin?

A: Official patient information states that a missed dose may be taken as soon as the omission is noticed. However, it is very important not to take a double dose to try and compensate for the missed one. After taking the missed dose, you may continue with your regular dosing schedule.

Q: Is it normal to feel slightly dizzy when first starting Silosin?

A: Yes, dizziness or lightheadedness when changing position (known as orthostatic hypotension) is listed as a common side effect of Silosin. This risk is typically highest when treatment is first initiated. A cautious approach, such as rising slowly from a sitting or lying position, is often recommended due to this effect.

Q: How long does Silosin stay in your system after stopping treatment?

A: Official pharmacokinetic studies indicate that the half-life of Silosin is approximately 13 hours. This is the time it takes for half of the drug to be eliminated from the body. Healthcare providers use this measurement to estimate how quickly the medication is cleared from the system.

Q: Is Silosin known to be addictive?

A: No, Silosin (silodosin) is not classified as a controlled substance by regulatory health agencies. It does not carry the risk of addiction.

Q: Are there any specific dietary restrictions to follow while taking Silosin?

A: Official information states that Silosin is to be taken with a meal. This timing helps maintain the drug's intended levels in the body. Additionally, regulatory warnings note that products containing grapefruit may increase the level of Silosin in the body.

Q: Does Silosin have any impact on blood pressure?

A: Yes, Silosin can cause a drop in blood pressure when changing posture (orthostatic hypotension), which is a documented side effect. However, Silosin is not approved or indicated for the treatment of high blood pressure (hypertension).

Q: Can Silosin cause changes in mood or sleep patterns?

A: General changes in mood or sleep patterns are not listed as common side effects in the official product information. However, adverse reactions may include common symptoms like headache or dizziness, which could potentially affect alertness or overall functioning.

Q: Can I take multivitamins at the same time as Silosin?

A: Regulatory information advises discussing the use of all medications, including any vitamins, herbal products, or supplements, with a healthcare provider. This helps inform the provider about all concomitant products, which is important for managing potential interactions.

Q: How often do people need follow-up appointments when on Silosin?

A: Official patient counseling information stresses the importance of keeping all scheduled medical and laboratory appointments while taking Silosin. Continued monitoring of symptoms and potential side effects by a healthcare provider may be necessary while taking the medicine.

Q: What is the experience of people who have been on Silosin long-term?

A: The main efficacy data is based on short-term controlled studies. Longer-term safety and patient response have been monitored in open-label extension studies for periods of up to one year. These extended studies help healthcare professionals contextualize how patients tolerate and respond to the medication over time.

Q: What are the early signs that Silosin is starting to work?

A: Silosin is intended to relax the muscles of the prostate and bladder neck. Early signs of its therapeutic effect are typically an improvement in lower urinary tract symptoms associated with BPH, such as frequency or weak flow. These changes are observed in the context of clinical studies.

Q: Are there generic versions of Silosin available?

A: Yes, Silosin is available as a generic version, which is known by its active ingredient name, silodosin. The generic form contains the same active drug as the brand-name product.

Q: Do clinical trials for Silosin include a diverse range of participants?

A: Clinical studies used to evaluate Silosin's efficacy were focused on adult men with moderate-to-severe BPH symptoms. The patient populations in these trials generally included participants with a mean age of approximately 64 years old.

Q: Are the side effects more pronounced at the beginning of treatment?

A: Official labeling notes that the risk of certain side effects, particularly orthostatic hypotension (dizziness), is generally highest when beginning treatment with Silosin. Many side effects are reported to diminish as the body adjusts to the medication, though this varies by individual.

Q: What happens if I take too much Silosin by mistake?

A: If an overdose of Silosin is suspected, symptoms may include severe dizziness, lightheadedness, fainting, or blurred vision. Emergency medical services should be contacted immediately if an overdose is suspected.

Q: What is the difference between Silosin and other similar sounding drugs I've seen advertised?

A: Silosin belongs to the class of medicines called alpha-blockers. It is specifically characterized in official documents as a highly selective competitive antagonist of the Alpha-1A Adrenoceptor, which is primarily concentrated in the prostate and bladder neck.

Q: Can Silosin affect fertility?

A: Yes, official safety information indicates that Silosin can cause retrograde ejaculation, a condition where semen is released into the bladder. This condition may temporarily affect male fertility. This effect is generally considered reversible upon discontinuation of treatment.

How should Silosin be stored and disposed of?

How to Store and Dispose of Silodosin

Silodosin capsules must be stored according to specific environmental and packaging requirements to ensure product stability, as outlined in regulatory documents.

Storage Requirements

  • Temperature: Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
  • Protection: The medicine must be kept protected from light and moisture.
  • Container: Store in the original package, and the container must be kept tightly closed.
  • Child Safety: Keep silodosin out of the sight and reach of children.
  • Stability: If the capsule contents are mixed with applesauce, the mixture must be used immediately (within 5 minutes) and must not be stored.

Disposal Instructions

Any unused or expired silodosin and related waste material must be disposed of in accordance with local requirements for medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Silosin found in:

A-Z Index: